Dyadic International Inc. (NASDAQ:DYAI) Short Interest Update

Dyadic International Inc. (NASDAQ:DYAI) saw a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 164,738 shares, an increase of 211.0% from the July 30th total of 52,977 shares. Based on an average daily volume of 206,606 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.6% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $3.00.

Institutional Investors Weigh In On Dyadic International

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International during the 2nd quarter worth approximately $50,000. BlackRock Inc. purchased a new stake in shares of Dyadic International during the 2nd quarter valued at approximately $177,000. Finally, Geode Capital Management LLC raised its position in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the period. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Trading Down 3.9%

Dyadic International stock traded down $0.03 during trading on Friday, reaching $0.61. 276,696 shares of the company were exchanged, compared to its average volume of 168,150. Dyadic International has a 52-week low of $0.60 and a 52-week high of $1.60. The company has a market capitalization of $22.38 million, a P/E ratio of -2.67 and a beta of 1.12. The company has a debt-to-equity ratio of 4.08, a current ratio of 1.65 and a quick ratio of 1.65. The stock’s 50 day simple moving average is $0.96 and its two-hundred day simple moving average is $0.85.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative net margin of 201.43% and a negative return on equity of 2,920.31%. The company had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $1.02 million. On average, equities research analysts expect that Dyadic International will post -0.15 earnings per share for the current fiscal year.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.